IGM Biosciences, Inc.
IGM Biosciences is pioneering a new class of antibody medicines for autoimmune and inflammatory diseases, utilizing engineered IgM antibodies to create 'super antibodies' with greater binding power and therapeutic potential. Their mission is to develop innovative antibody therapies that expand treatment options and improve patient outcomes.
Industries
Nr. of Employees
large (251-1000)
IGM Biosciences, Inc.
325 E Middlefield Road, Mountain View, CA 94043
Patents
Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
US-11578131-B2
View DetailsModified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US-11401337-B2
View Details
Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
US-11578131-B2
View DetailsModified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US-11401337-B2
View DetailsProducts
Intranasal multivalent IgM antiviral antibody for SARS‑CoV‑2
An IgM‑format neutralizing antibody developed for intranasal administration to prevent and treat SARS‑CoV‑2 infection with higher neutralizing potency compared with corresponding IgG antibodies in preclinical studies.
Bispecific IgM T‑cell engager targeting CD20 and CD3 for B‑cell mediated autoimmune diseases
A bispecific IgM format that binds CD20 with multiple binding units and engages CD3 on T cells to deplete B cells; evaluated in Phase 1b trials for autoimmune indications.
CD38xCD3 bispecific IgM T‑cell engager for hematologic/autoimmune indications
A bispecific IgM designed to target CD38‑expressing plasma cells and engage T cells to reduce autoreactive antibody‑producing cells; intended for diseases such as generalized myasthenia gravis.
DR5‑targeting multivalent IgM agonist for colorectal cancer
A multimeric IgM agonist targeting death receptor 5 (DR5) engineered to cross‑link receptors and induce apoptosis in tumor cells; evaluated in combination trials with ADCs or chemotherapies.
Anti‑PD‑L1 IgM fused to IL‑15 cytokine for targeted immune stimulation
An IgM antibody targeting PD‑L1 with an IL‑15 cytokine fusion designed to localize immune stimulation to PD‑L1‑expressing cells and enhance NK and CD8+ T cell proliferation and tumor cytotoxicity.
CD123‑directed IgM T‑cell engager with minimized cytokine release
A multivalent IgM T‑cell engager targeting CD123 developed to demonstrate potent in vitro and in vivo activity with limited systemic cytokine release.
Intranasal multivalent IgM antiviral antibody for SARS‑CoV‑2
An IgM‑format neutralizing antibody developed for intranasal administration to prevent and treat SARS‑CoV‑2 infection with higher neutralizing potency compared with corresponding IgG antibodies in preclinical studies.
Bispecific IgM T‑cell engager targeting CD20 and CD3 for B‑cell mediated autoimmune diseases
A bispecific IgM format that binds CD20 with multiple binding units and engages CD3 on T cells to deplete B cells; evaluated in Phase 1b trials for autoimmune indications.
CD38xCD3 bispecific IgM T‑cell engager for hematologic/autoimmune indications
A bispecific IgM designed to target CD38‑expressing plasma cells and engage T cells to reduce autoreactive antibody‑producing cells; intended for diseases such as generalized myasthenia gravis.
DR5‑targeting multivalent IgM agonist for colorectal cancer
A multimeric IgM agonist targeting death receptor 5 (DR5) engineered to cross‑link receptors and induce apoptosis in tumor cells; evaluated in combination trials with ADCs or chemotherapies.
Anti‑PD‑L1 IgM fused to IL‑15 cytokine for targeted immune stimulation
An IgM antibody targeting PD‑L1 with an IL‑15 cytokine fusion designed to localize immune stimulation to PD‑L1‑expressing cells and enhance NK and CD8+ T cell proliferation and tumor cytotoxicity.
CD123‑directed IgM T‑cell engager with minimized cytokine release
A multivalent IgM T‑cell engager targeting CD123 developed to demonstrate potent in vitro and in vivo activity with limited systemic cytokine release.
Expertise Areas
- Multivalent IgM antibody engineering
- Bispecific T‑cell engager development
- Targeted cytokine fusion therapeutics
- Preclinical in vitro and in vivo pharmacology
Key Technologies
- Multivalent IgM antibody format
- Bispecific antibody engineering (T cell engagers)
- Cytokine–antibody fusion (IL‑15 fusion)
- Targeted cytokine delivery to PD‑L1+ cells
News & Updates
Participation in the EULAR 2024 Congress to present research and developments.
Participation in the 64th ASH Annual Meeting and Exposition in December 2022.
Presentations at the AACR Annual Meeting in April 2024, including research on IGM-2644 and other antibody therapies.
Participation in the EULAR 2024 Congress to present research and developments.
Participation in the 64th ASH Annual Meeting and Exposition in December 2022.
Presentations at the AACR Annual Meeting in April 2024, including research on IGM-2644 and other antibody therapies.